Glucose metabolism | R-HSA-70326 | 6.77 |
Toll Like Receptor 4 (TLR4) Cascade | R-HSA-166016 | 6.11 |
Cell Cycle | R-HSA-1640170 | 3.89 |
Developmental Biology | R-HSA-1266738 | 3.48 |
Recruitment of mitotic centrosome proteins and complexes | R-HSA-380270 | 6.68 |
Signaling by VEGF | R-HSA-194138 | 4.66 |
Organelle biogenesis and maintenance | R-HSA-1852241 | 4.63 |
FCERI mediated MAPK activation | R-HSA-2871796 | 4.32 |
Toll Like Receptor 3 (TLR3) Cascade | R-HSA-168164 | 6.47 |
Beta-catenin phosphorylation cascade | R-HSA-196299 | 8.89 |
Signaling by EGFR | R-HSA-177929 | 4.59 |
AXIN mutants destabilize the destruction complex, activating WNT signaling | R-HSA-4839735 | 9.18 |
Platelet homeostasis | R-HSA-418346 | 6.68 |
Nuclear Events (kinase and transcription factor activation) | R-HSA-198725 | 8.4 |
VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 4.7 |
Spry regulation of FGF signaling | R-HSA-1295596 | 9.18 |
Interleukin-2 signaling | R-HSA-451927 | 5.05 |
MAP kinase activation in TLR cascade | R-HSA-450294 | 7.28 |
MyD88-independent TLR3/TLR4 cascade | R-HSA-166166 | 6.47 |
truncations of AMER1 destabilize the destruction complex | R-HSA-5467348 | 9.18 |
Toll Like Receptor TLR1:TLR2 Cascade | R-HSA-168179 | 6.51 |
misspliced GSK3beta mutants stabilize beta-catenin | R-HSA-5339716 | 9.08 |
S33 mutants of beta-catenin aren't phosphorylated | R-HSA-5358747 | 9.08 |
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | R-HSA-975957 | 6.25 |
Toll Like Receptor 5 (TLR5) Cascade | R-HSA-168176 | 6.73 |
S37 mutants of beta-catenin aren't phosphorylated | R-HSA-5358749 | 9.08 |
FRS-mediated FGFR4 signaling | R-HSA-5654712 | 5.14 |
Downstream signaling of activated FGFR4 | R-HSA-5654716 | 4.71 |
Signaling by ERBB2 | R-HSA-1227986 | 4.66 |
VEGFR2 mediated cell proliferation | R-HSA-5218921 | 5.07 |
Opioid Signalling | R-HSA-111885 | 6.64 |
ERK/MAPK targets | R-HSA-198753 | 8.59 |
Immune System | R-HSA-168256 | 2.37 |
Frs2-mediated activation | R-HSA-170968 | 5.12 |
Downstream signal transduction | R-HSA-186763 | 4.65 |
Loss of Nlp from mitotic centrosomes | R-HSA-380259 | 7.03 |
RAF activation | R-HSA-5673000 | 8.34 |
RAF/MAP kinase cascade | R-HSA-5673001 | 5.15 |
T41 mutants of beta-catenin aren't phosphorylated | R-HSA-5358752 | 9.08 |
MAPK targets/ Nuclear events mediated by MAP kinases | R-HSA-450282 | 8.08 |
Toll Like Receptor 10 (TLR10) Cascade | R-HSA-168142 | 6.73 |
Mitotic Metaphase and Anaphase | R-HSA-2555396 | 5.45 |
Signalling to p38 via RIT and RIN | R-HSA-187706 | 5.12 |
CTLA4 inhibitory signaling | R-HSA-389513 | 8.52 |
FRS-mediated FGFR2 signaling | R-HSA-5654700 | 5.14 |
Cell Cycle, Mitotic | R-HSA-69278 | 4.16 |
FRS-mediated FGFR3 signaling | R-HSA-5654706 | 5.14 |
Cyclin A/B1 associated events during G2/M transition | R-HSA-69273 | 8.52 |
Downstream signaling of activated FGFR3 | R-HSA-5654708 | 4.71 |
G2/M Transition | R-HSA-69275 | 6.06 |
Mitotic G1-G1/S phases | R-HSA-453279 | 5.91 |
Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 4.03 |
G1/S Transition | R-HSA-69206 | 6.21 |
Interleukin receptor SHC signaling | R-HSA-912526 | 5.09 |
Innate Immune System | R-HSA-168249 | 3.17 |
Mitotic G2-G2/M phases | R-HSA-453274 | 6.04 |
Integration of energy metabolism | R-HSA-163685 | 6.24 |
TCF dependent signaling in response to WNT | R-HSA-201681 | 5.36 |
Anchoring of the basal body to the plasma membrane | R-HSA-5620912 | 6.51 |
Mitotic Anaphase | R-HSA-68882 | 5.46 |
NGF signalling via TRKA from the plasma membrane | R-HSA-187037 | 4.51 |
Prolonged ERK activation events | R-HSA-169893 | 5.11 |
Signaling by Wnt | R-HSA-195721 | 4.79 |
Signaling by FGFR2 | R-HSA-5654738 | 4.68 |
GRB2 events in EGFR signaling | R-HSA-179812 | 5.15 |
Signaling by FGFR1 | R-HSA-5654736 | 4.69 |
TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | R-HSA-975138 | 6.72 |
Negative regulation of FGFR4 signaling | R-HSA-5654733 | 8.03 |
MyD88 cascade initiated on plasma membrane | R-HSA-975871 | 6.73 |
DAP12 interactions | R-HSA-2172127 | 4.56 |
ERKs are inactivated | R-HSA-202670 | 9.4 |
Axon guidance | R-HSA-422475 | 3.93 |
Nonsense-Mediated Decay (NMD) | R-HSA-927802 | 6.25 |
Mitotic Prometaphase | R-HSA-68877 | 6.08 |
Mitotic Prophase | R-HSA-68875 | 6.27 |
TRIF-mediated TLR3/TLR4 signaling | R-HSA-937061 | 6.47 |
Toll Like Receptor 2 (TLR2) Cascade | R-HSA-181438 | 6.51 |
Signaling by Leptin | R-HSA-2586552 | 5.1 |
IGF1R signaling cascade | R-HSA-2428924 | 4.85 |
IRS-related events triggered by IGF1R | R-HSA-2428928 | 4.85 |
M Phase | R-HSA-68886 | 4.87 |
IRS-mediated signalling | R-HSA-112399 | 4.87 |
Signaling by Insulin receptor | R-HSA-74752 | 4.73 |
Disease | R-HSA-1643685 | 3.33 |
Insulin receptor signalling cascade | R-HSA-74751 | 4.85 |
Downstream signaling of activated FGFR1 | R-HSA-5654687 | 4.71 |
Metabolism of carbohydrates | R-HSA-71387 | 4.93 |
MASTL Facilitates Mitotic Progression | R-HSA-2465910 | 9.66 |
Gene Expression | R-HSA-74160 | 2.72 |
Gastrin-CREB signalling pathway via PKC and MAPK | R-HSA-881907 | 4.26 |
Negative regulation of FGFR1 signaling | R-HSA-5654726 | 7.98 |
Negative regulation of FGFR2 signaling | R-HSA-5654727 | 7.89 |
Toll-Like Receptors Cascades | R-HSA-168898 | 5.91 |
Inhibition of replication initiation of damaged DNA by RB1/E2F1 | R-HSA-113501 | 9.4 |
Toll Like Receptor TLR6:TLR2 Cascade | R-HSA-168188 | 6.56 |
Diseases of signal transduction | R-HSA-5663202 | 4.89 |
GRB2 events in ERBB2 signaling | R-HSA-1963640 | 5.15 |
Toll Like Receptor 7/8 (TLR7/8) Cascade | R-HSA-168181 | 6.68 |
Signalling to RAS | R-HSA-167044 | 5.08 |
Glycolysis | R-HSA-70171 | 8.03 |
Downstream signaling of activated FGFR2 | R-HSA-5654696 | 4.71 |
SHC1 events in EGFR signaling | R-HSA-180336 | 5.15 |
FRS-mediated FGFR1 signaling | R-HSA-5654693 | 5.14 |
APC truncation mutants have impaired AXIN binding | R-HSA-5467337 | 9.18 |
SHC1 events in ERBB2 signaling | R-HSA-1250196 | 5.15 |
Signaling by WNT in cancer | R-HSA-4791275 | 7.89 |
ARMS-mediated activation | R-HSA-170984 | 5.12 |
PP2A-mediated dephosphorylation of key metabolic factors | R-HSA-163767 | 10.18 |
MyD88 dependent cascade initiated on endosome | R-HSA-975155 | 6.68 |
MyD88:Mal cascade initiated on plasma membrane | R-HSA-166058 | 6.56 |
Signalling to ERKs | R-HSA-187687 | 5.04 |
Signaling by PDGF | R-HSA-186797 | 4.53 |
Activated TLR4 signalling | R-HSA-166054 | 6.27 |
E2F mediated regulation of DNA replication | R-HSA-113510 | 7.94 |
Regulation of PLK1 Activity at G2/M Transition | R-HSA-2565942 | 6.66 |
Toll Like Receptor 9 (TLR9) Cascade | R-HSA-168138 | 6.62 |
Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | R-HSA-2404192 | 4.85 |
Separation of Sister Chromatids | R-HSA-2467813 | 5.55 |
Signaling by Interleukins | R-HSA-449147 | 4.71 |
Initiation of Nuclear Envelope Reformation | R-HSA-2995383 | 9.28 |
Signaling by Rho GTPases | R-HSA-194315 | 4.43 |
Negative regulation of FGFR3 signaling | R-HSA-5654732 | 8.12 |
Cytokine Signaling in Immune system | R-HSA-1280215 | 3.74 |
SOS-mediated signalling | R-HSA-112412 | 5.15 |
Metabolism | R-HSA-1430728 | 2.34 |
disassembly of the destruction complex and recruitment of AXIN to the membrane | R-HSA-4641262 | 8.03 |
Signaling by ERBB4 | R-HSA-1236394 | 4.7 |
Assembly of the primary cilium | R-HSA-5617833 | 5.44 |
MAPK1/MAPK3 signaling | R-HSA-5684996 | 5.11 |
Adaptive Immune System | R-HSA-1280218 | 3.19 |
DARPP-32 events | R-HSA-180024 | 8.4 |
MAPK family signaling cascades | R-HSA-5683057 | 4.89 |
Signalling by NGF | R-HSA-166520 | 4.23 |
G1 Phase | R-HSA-69236 | 7.73 |
AXIN missense mutants destabilize the destruction complex | R-HSA-5467340 | 9.18 |
Cyclin D associated events in G1 | R-HSA-69231 | 7.73 |
Platelet sensitization by LDL | R-HSA-432142 | 8.89 |
Costimulation by the CD28 family | R-HSA-388841 | 6.56 |
Signaling by FGFR4 | R-HSA-5654743 | 4.69 |
Signaling by FGFR3 | R-HSA-5654741 | 4.69 |
RHO GTPases Activate Formins | R-HSA-5663220 | 6.01 |
Signaling by FGFR | R-HSA-190236 | 4.67 |
Loss of proteins required for interphase microtubule organization from the centrosome | R-HSA-380284 | 7.03 |
Centrosome maturation | R-HSA-380287 | 6.68 |
SHC1 events in ERBB4 signaling | R-HSA-1250347 | 5.15 |
Signaling by SCF-KIT | R-HSA-1433557 | 4.73 |
NCAM signaling for neurite out-growth | R-HSA-375165 | 4.9 |
S45 mutants of beta-catenin aren't phosphorylated | R-HSA-5358751 | 9.08 |
DAP12 signaling | R-HSA-2424491 | 4.64 |
Interleukin-3, 5 and GM-CSF signaling | R-HSA-512988 | 4.99 |
Resolution of Sister Chromatid Cohesion | R-HSA-2500257 | 6.18 |
Negative regulation of MAPK pathway | R-HSA-5675221 | 7.66 |
RHO GTPase Effectors | R-HSA-195258 | 4.94 |
Signaling by GPCR | R-HSA-372790 | 2.68 |
Degradation of beta-catenin by the destruction complex | R-HSA-195253 | 6.64 |
truncated APC mutants destabilize the destruction complex | R-HSA-4839744 | 9.18 |
phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex | R-HSA-4839743 | 9.08 |
AMER1 mutants destabilize the destruction complex | R-HSA-4839748 | 9.18 |
Hemostasis | R-HSA-109582 | 3.98 |
Signal Transduction | R-HSA-162582 | 1.78 |
Nuclear Envelope Reassembly | R-HSA-2995410 | 9.28 |